Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus

Journal of Infectious Diseases

Volumn 198, Issue 7, 2008, Pages 1007-1015

  Shinoff, Joshua J ^a,b   O'Brien, Katherine L ^a   Thumar, Bhagvanji ^a   Shaw, Jana B ^a,c   Reid, Raymond ^a   Hua, Wei ^a,d   Santosham, Mathuram ^a   Karron, Ruth A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b APPLIED BIOSYSTEMS   (United States)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; HOSPITALIZATION; HUMAN; HUMORAL IMMUNITY; INFANT; INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS;

AGE FACTORS; ANTIBODIES, VIRAL; HUMANS; INFANT; INFANT, NEWBORN; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; VACCINES, ATTENUATED;

EID: 51849108676     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591460     Document Type: Article

References (47)

1. Hall CB. Prospects for a respiratory syncytial virus vaccine. Science 1994; 265:1393- 4.
2. Collins PL, Crowe JE Jr. Respiratory syncytial virus and metapneumovirus. In: Knipe DM, Howley PM, eds. Fields virology. 5th ed. Vol 2. Philadelphia: Lippincott Williams & Wilkins, 2007:1601- 46.
3. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991; 88:527-32.
4. Berkovich S. Acute respiratory illness in the premature nursery associated with respiratory syncytial virus infections. Pediatrics 1964; 34:753-60.
5. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199-203.
6. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982; 307:397-400.
7. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics 2003; 112:1447-52.
8. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1442-6.
9. Prince GA, Hemming VG, Horswood RL, Chanock RM. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 1985; 3:193-206.
10. Prince GA, Horswood RL, Chanock RM. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985; 55:517-20.
11. Groothuis JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-30.
12. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. IMpact-RSV Study Group. Pediatrics 1998; 102:531-7.
13. Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986; 24:894-8.
14. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
15. Cane PA, Thomas HM, Simpson AF, Evans JE, Hart CA, Pringle CR. Analysis of the human serological immune response to a variable region of the attachment (G) protein of respiratory syncytial virus during primary infection. J Med Virol 1996; 48:253-61.
16. Garcia-Barreno B, Palomo C, Penas C, Delgado T, Perez-Brena P, Melero JA. Marked differences in the antigenic structure of human respiratory syncytial virus F and G glycoproteins. J Virol 1989; 63:925-32.
17. Bockova J, O'Brien KL, Oski J, et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002; 110:e20.
18. Moulton LH, O'Brien KL, Kohberger R, et al. Design of a group-randomized streptococcus pneumoniae vaccine trial. Controlled Clin Trials 2001; 22:438-52.
19. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966; 83:299-313.
20. Feldman SA, Hendry RM, Beeler JA. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol 1999; 73:6610-7.
21. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52:97-104.
22. Richardson LS, Yolken RH, Belshe RB, et al. Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect Immun 1978; 20:660-4.
23. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis 1978; 138:24-32.
24. Crowe JE. Respiratory syncytial virus vaccine development. Vaccine 2001; 20(Suppl 1):S32-7.
25. Durbin AP, Karron RA. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis 2003; 37:1668-77.
26. Karron RA, Singleton RJ, Bulkow LR, et al. Severe respiratory syncytial virus disease in Alaska Native children. J Infect Dis 1999; 180:41-9.
27. Lowther SA, Shay DK, Holman RC, Clark MJ, Kaufman SF, Anderson LJ. Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children. Pediatr Infect Dis J 2000; 19:11-7.
28. Centers for Disease Control and Prevention. Bronchiolitis-associated outpatient visits and hospitalizations among American Indian and Alaska Native children: United States, 1990-2000. MMWR 2003; 52:707-10.
29. Glezen WP, Paredes A, Allison JE, Taber LH, Frank AL. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981; 98:708-15.
30. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543-6.
31. Holberg CJ, Wright AL, Martinez FD, Ray CG, Taussig LM, Lebowitz MD. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991; 133:1135-51.
32. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
33. Norrby E, Mufson MA, Alexander H, Houghten RA, Lerner RA. Site-directed serology with synthetic peptides representing the large glycoprotein G of respiratory syncytial virus. Proc Natl Acad Sci USA 1987; 84:6572-6.
34. Akerlind-Stopner B, Utter G, Norrby E, Mufson MA. Evaluation of subgroup-specific peptides of the G protein of respiratory syncytial virus for characterization of the immune response. J Med Virol 1995; 47:120-5.
35. Cane PA. Analysis of linear epitopes recognised by the primary human antibody response to a variable region of the attachment (G) protein of respiratory syncytial virus. J Med Virol 1997; 51:297-304.
36. Hendricks DA, McIntosh K, Patterson JL. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 1988; 62:2228-33.
37. Teng MN, Collins PL. The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo. J Virol 2002; 76:6164-71.
38. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2001; 2:732- 8.
39. Sparer TE, Matthews S, Hussell T, et al. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 1998; 187:1921-6.
40. Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998; 188:1967-72.
41. Bukreyev A, Serra ME, Laham FR, et al. The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes. J Virol 2006; 80:5854-61.
42. Harcourt JL, Karron RA, Anderson LJ, Tripp RA. Antibody responses to RSV are associated with inhibition of RSV G glycoprotein binding to CX3CR1 and G glycoprotein-mediated leukocyte chemotaxis. J Infect Dis 2004; 190:1936-40.
43. Wright PF, Gruber WC, Peters M, et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2002; 185:1011-8.
44. Crowe JE Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Clin Infect Dis 2001; 33:1720-7.
45. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis 2005; 191:1861-8.
46. Elliott MB, Pryharski KS, Yu Q, et al. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. J Virol 2004; 78:8446-54.
47. Karron RA. Respiratory syncytial virus and parainfluenza virus vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines: expert consult. 5th ed. Philadelphia: Saunders, 2008: 1283-94.